000303427 001__ 303427
000303427 005__ 20250809114439.0
000303427 0247_ $$2doi$$a10.1111/jop.70015
000303427 0247_ $$2pmid$$apmid:40772503
000303427 0247_ $$2ISSN$$a0300-9777
000303427 0247_ $$2ISSN$$a0904-2512
000303427 0247_ $$2ISSN$$a1600-0714
000303427 037__ $$aDKFZ-2025-01652
000303427 041__ $$aEnglish
000303427 082__ $$a610
000303427 1001_ $$00009-0002-8268-7485$$aRinne, Sanni$$b0
000303427 245__ $$aEpstein-Barr Virus Serology Associated With Persistent Oral Human Papillomavirus Infections in Men.
000303427 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000303427 3367_ $$2DRIVER$$aarticle
000303427 3367_ $$2DataCite$$aOutput Types/Journal article
000303427 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754660961_12815
000303427 3367_ $$2BibTeX$$aARTICLE
000303427 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303427 3367_ $$00$$2EndNote$$aJournal Article
000303427 500__ $$aepub
000303427 520__ $$aMost people acquire Epstein-Barr virus (EBV) and certain human papillomaviruses (HPVs) during their lifetime. HPV-related oropharyngeal carcinomas have increased in recent decades, particularly among men. The role of coinfection with viruses like EBV on HPV outcomes is unclear. We investigated potential associations between EBV serology and longitudinal outcomes of oral HPV infections in men.This study included 119 men from the Finnish Family HPV Study who were followed up for 3 years. Blood and oral cavity samples were collected at baseline, 12-, 24-, and 36-month follow-up visits. HPV was genotyped with the Multimetrix assay, and the serum IgG antibodies of EBV proteins Zebra, EA-D, EBNA, and VCAp18 were measured with fluorescent bead-based multiplex serology. Univariate regression analysis was used to measure the strength of the association between different variables.Most participants (99.2%; n = 118) were EBV-seropositive with stable antibody titers throughout the follow-up. Self-reported history of atopy was positively associated with elevated EBNA-1 levels, with OR 7.43 (95% CI: 1.39-39.76). EBV seropositivity with high titers and elevated EA-D levels alone increased the risk of type-specific oral HPV persistence for Types 16, 18, 33, and 51, with OR 4.20 (95% CI: 1.09-16.19) and OR 6.23 (95% CI: 1.19-32.75), respectively.Most of the participants were EBV-seropositive as expected. Elevated EA-D antibody levels and being EBV-seropositive with high titers significantly increased the risk of type-specific oral HPV persistence among these men.
000303427 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000303427 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303427 650_7 $$2Other$$aEBV antibodies
000303427 650_7 $$2Other$$aEBV serology
000303427 650_7 $$2Other$$aEpstein–Barr virus (EBV)
000303427 650_7 $$2Other$$ahuman papillomavirus (HPV)
000303427 650_7 $$2Other$$aoral HPV infections
000303427 7001_ $$0P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e$$aMichels, Birgitta$$b1$$udkfz
000303427 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia$$b2$$udkfz
000303427 7001_ $$aSyrjänen, Kari$$b3
000303427 7001_ $$aGrenman, Seija$$b4
000303427 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b5$$udkfz
000303427 7001_ $$aSyrjänen, Stina$$b6
000303427 7001_ $$aLouvanto, Karolina$$b7
000303427 773__ $$0PERI:(DE-600)2026385-5$$a10.1111/jop.70015$$gp. jop.70015$$pnn$$tJournal of oral pathology & medicine$$vnn$$x0300-9777$$y2025
000303427 909CO $$ooai:inrepo02.dkfz.de:303427$$pVDB
000303427 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000303427 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000303427 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000303427 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000303427 9141_ $$y2025
000303427 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000303427 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-11$$wger
000303427 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ORAL PATHOL MED : 2022$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000303427 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000303427 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x0
000303427 980__ $$ajournal
000303427 980__ $$aVDB
000303427 980__ $$aI:(DE-He78)D320-20160331
000303427 980__ $$aUNRESTRICTED